Wedbush Brokers Increase Earnings Estimates for ZNTL

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL - Free Report) - Wedbush boosted their Q2 2025 earnings estimates for shares of Zentalis Pharmaceuticals in a report released on Thursday, May 15th. Wedbush analyst R. Driscoll now expects that the company will earn ($0.57) per share for the quarter, up from their prior estimate of ($0.66). Wedbush currently has a "Neutral" rating and a $4.00 target price on the stock. The consensus estimate for Zentalis Pharmaceuticals' current full-year earnings is ($2.42) per share. Wedbush also issued estimates for Zentalis Pharmaceuticals' Q3 2025 earnings at ($0.58) EPS, Q4 2025 earnings at ($0.42) EPS, FY2025 earnings at ($2.19) EPS, FY2026 earnings at ($1.74) EPS, FY2027 earnings at ($1.42) EPS, FY2028 earnings at ($0.73) EPS and FY2029 earnings at ($0.17) EPS.

ZNTL has been the subject of several other reports. UBS Group dropped their target price on Zentalis Pharmaceuticals from $5.00 to $2.20 and set a "neutral" rating for the company in a report on Tuesday, January 28th. HC Wainwright reissued a "buy" rating and set a $10.00 price objective on shares of Zentalis Pharmaceuticals in a research note on Thursday, May 15th. Finally, Wells Fargo & Company dropped their price target on shares of Zentalis Pharmaceuticals from $8.00 to $6.00 and set an "equal weight" rating for the company in a research report on Thursday, January 30th. Five investment analysts have rated the stock with a hold rating and four have issued a buy rating to the company's stock. According to data from MarketBeat, Zentalis Pharmaceuticals currently has a consensus rating of "Hold" and an average target price of $8.24.

Zentalis Pharmaceuticals Stock Performance

ZNTL stock traded down $0.04 during trading on Monday, hitting $1.20. 778,244 shares of the company traded hands, compared to its average volume of 1,554,957. The firm has a market capitalization of $86.34 million, a PE ratio of -0.48 and a beta of 1.81. Zentalis Pharmaceuticals has a 1 year low of $1.01 and a 1 year high of $13.00. The company has a 50-day moving average of $1.38 and a 200-day moving average of $2.26.

Zentalis Pharmaceuticals (NASDAQ:ZNTL - Get Free Report) last posted its quarterly earnings results on Wednesday, May 14th. The company reported ($0.67) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.67).

Insiders Place Their Bets

In related news, Director Scott Dunseth Myers purchased 21,000 shares of Zentalis Pharmaceuticals stock in a transaction that occurred on Wednesday, April 30th. The shares were bought at an average price of $1.40 per share, for a total transaction of $29,400.00. Following the completion of the transaction, the director now directly owns 281,192 shares of the company's stock, valued at $393,668.80. This represents a 8.07% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Company insiders own 1.90% of the company's stock.

Hedge Funds Weigh In On Zentalis Pharmaceuticals

Several hedge funds and other institutional investors have recently modified their holdings of the stock. Millennium Management LLC grew its holdings in shares of Zentalis Pharmaceuticals by 220.6% during the 1st quarter. Millennium Management LLC now owns 3,069,514 shares of the company's stock worth $4,881,000 after acquiring an additional 2,111,951 shares during the period. Acadian Asset Management LLC grew its holdings in shares of Zentalis Pharmaceuticals by 150.6% during the 1st quarter. Acadian Asset Management LLC now owns 2,674,035 shares of the company's stock worth $4,244,000 after acquiring an additional 1,606,802 shares during the period. Almitas Capital LLC grew its holdings in shares of Zentalis Pharmaceuticals by 5.2% during the 1st quarter. Almitas Capital LLC now owns 1,710,921 shares of the company's stock worth $2,720,000 after acquiring an additional 84,025 shares during the period. Primecap Management Co. CA grew its stake in Zentalis Pharmaceuticals by 1.5% in the fourth quarter. Primecap Management Co. CA now owns 1,520,630 shares of the company's stock worth $4,608,000 after purchasing an additional 22,600 shares during the period. Finally, Geode Capital Management LLC grew its stake in Zentalis Pharmaceuticals by 1.6% in the fourth quarter. Geode Capital Management LLC now owns 1,312,964 shares of the company's stock worth $3,979,000 after purchasing an additional 20,864 shares during the period.

About Zentalis Pharmaceuticals

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.